Evidence map›Paper›PMID 28575677›Full record

ArticleCell2017

Curbing Tregs' (Lack of) Enthusiasm.

Taha Merghoub, Jedd D Wolchok

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms.Recent patents on anti-cancer drug discovery · 2025
    Review
  2. Article
  3. Article
  4. Tregs: Where We Are and What Comes Next?Frontiers in immunology · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Taha MerghoubMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Ludwig Institute for Cancer Research, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, New York, NY 10065, USA. Electronic address: merghout@mskcc.org.
Jedd D WolchokMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Ludwig Institute for Cancer Research, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, New York, NY 10065, USA; Weill Cornell Medicine, Cornell University, New York, NY 10065, USA. Electronic address: wolchokj@mskcc.org.
Cornell University · USParker Institute for Cancer Immunotherapy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue, Overacre-Delgoffe et al. show that interferon gamma production by a subset of regulatory T cells in the tumor microenvironment triggers Treg instability locally and restores anti-tumor immunity.

Indexed as

Tumor MicroenvironmentHumansT-Lymphocytes, Regulatory

Identifiers

PMID28575677
OpenAlexW2621219748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.